<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>大叔快评 | wechat-feeds</title><link>http://MzA3NzY1MjAzNg.favicon.privacyhide.com/favicon.ico</link><description>肿瘤学临床研究及制药企业研发评述</description><managingEditor> (hellodword)</managingEditor><pubDate>Fri, 30 Apr 2021 19:21:06 +0800</pubDate><image><url>http://MzA3NzY1MjAzNg.favicon.privacyhide.com/favicon.ico</url><title>大叔快评 | wechat-feeds</title><link>http://MzA3NzY1MjAzNg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>读NEJM 涨知识 I 溶瘤病毒治疗儿童高分级胶质瘤</title><link>https://mp.weixin.qq.com/s/kkjOm3twIs760poZxvlUZQ</link><description></description><content:encoded><![CDATA[读NEJM 涨知识 I 溶瘤病毒治疗儿童高分级胶质瘤]]></content:encoded><pubDate>Fri, 30 Apr 2021 12:24:52 +0800</pubDate></item><item><title>武田注射用维拉苷酶α获批进入中国</title><link>https://mp.weixin.qq.com/s/5bgGe-HS9dapMwsbW3UWsA</link><description></description><content:encoded><![CDATA[武田注射用维拉苷酶α获批进入中国]]></content:encoded><pubDate>Fri, 30 Apr 2021 12:24:52 +0800</pubDate></item><item><title>速度关注！这5项研究将亮相2021 ASCO年会全体大会</title><link>https://mp.weixin.qq.com/s/C0uj-zzEii5VIRyPhXqkuA</link><description></description><content:encoded><![CDATA[速度关注！这5项研究将亮相2021 ASCO年会全体大会]]></content:encoded><pubDate>Thu, 29 Apr 2021 21:19:51 +0800</pubDate></item><item><title>MM学院｜髓文月谈三月刊---多发性骨髓瘤月度文献新进展</title><link>https://mp.weixin.qq.com/s/Stz1LaXxDbIVsVlmymjAMQ</link><description></description><content:encoded><![CDATA[MM学院｜髓文月谈三月刊---多发性骨髓瘤月度文献新进展]]></content:encoded><pubDate>Thu, 29 Apr 2021 21:19:51 +0800</pubDate></item><item><title>专访 | 徐志宏教授：血友病性骨关节病的手术治疗</title><link>https://mp.weixin.qq.com/s/xbSRRXi9rvcyjTgIgLaESg</link><description></description><content:encoded><![CDATA[专访 | 徐志宏教授：血友病性骨关节病的手术治疗]]></content:encoded><pubDate>Thu, 29 Apr 2021 21:19:51 +0800</pubDate></item><item><title>读新闻 涨知识 I 武田新药Mobocertinib获得FDA优先审评</title><link>https://mp.weixin.qq.com/s/KIlQUUpHWlZn5ESFitoOOw</link><description></description><content:encoded><![CDATA[读新闻 涨知识 I 武田新药Mobocertinib获得FDA优先审评]]></content:encoded><pubDate>Wed, 28 Apr 2021 16:48:56 +0800</pubDate></item><item><title>读NEJM 涨知识 I FDA开始清算PD-1/L-1加速批准的验证性研究</title><link>https://mp.weixin.qq.com/s/hllLTJRG0vQKGacy5kJyuQ</link><description></description><content:encoded><![CDATA[读NEJM 涨知识 I FDA开始清算PD-1/L-1加速批准的验证性研究]]></content:encoded><pubDate>Tue, 27 Apr 2021 21:39:57 +0800</pubDate></item><item><title>白蛋白紫杉醇VS多西他赛二线治疗晚期NSCLC三期临床结果</title><link>https://mp.weixin.qq.com/s/QenZxLBEP2U2gyPA4YeTkg</link><description></description><content:encoded><![CDATA[白蛋白紫杉醇VS多西他赛二线治疗晚期NSCLC三期临床结果]]></content:encoded><pubDate>Tue, 27 Apr 2021 21:39:57 +0800</pubDate></item><item><title>专访 | 梅恒教授：CAR-T治疗淋巴瘤的最新进展 | 中华医学会第一次全国淋巴细胞疾病学术大会</title><link>https://mp.weixin.qq.com/s/y4QWz-v6vhxJxL_b4iU7lw</link><description></description><content:encoded><![CDATA[专访 | 梅恒教授：CAR-T治疗淋巴瘤的最新进展 | 中华医学会第一次全国淋巴细胞疾病学术大会]]></content:encoded><pubDate>Tue, 27 Apr 2021 21:39:57 +0800</pubDate></item><item><title>【2809】【巅峰对话】程颖教授谈SCLC诊疗指南更新概况及SCLC探索方向</title><link>https://mp.weixin.qq.com/s/-dybCWhW2FlyyELXzCk4XA</link><description></description><content:encoded><![CDATA[【2809】【巅峰对话】程颖教授谈SCLC诊疗指南更新概况及SCLC探索方向]]></content:encoded><pubDate>Tue, 27 Apr 2021 21:39:57 +0800</pubDate></item><item><title>崔国惠教授点评 | BV联合PD-1治疗原发纵膈弥漫大B细胞淋巴瘤一例</title><link>https://mp.weixin.qq.com/s/vVS38VxDsZHVxYT_B9fNGA</link><description></description><content:encoded><![CDATA[崔国惠教授点评 | BV联合PD-1治疗原发纵膈弥漫大B细胞淋巴瘤一例]]></content:encoded><pubDate>Mon, 26 Apr 2021 22:07:05 +0800</pubDate></item><item><title>重磅 | 2021 CSCO儿童及青少年白血病诊疗指南全新发布！</title><link>https://mp.weixin.qq.com/s/pGHeuiCT9MINs38oYgLmEg</link><description></description><content:encoded><![CDATA[重磅 | 2021 CSCO儿童及青少年白血病诊疗指南全新发布！]]></content:encoded><pubDate>Mon, 26 Apr 2021 22:07:05 +0800</pubDate></item><item><title>胃癌热议话题的医学伦理问题</title><link>https://mp.weixin.qq.com/s/DOcEBvu7l0hLY_v1unet0g</link><description></description><content:encoded><![CDATA[胃癌热议话题的医学伦理问题]]></content:encoded><pubDate>Sun, 25 Apr 2021 15:39:10 +0800</pubDate></item><item><title>四代ALK抑制剂TPX-0131开启1/2期临床研究</title><link>https://mp.weixin.qq.com/s/_rQtXGHe-PvyI1qfj9Gtfw</link><description></description><content:encoded><![CDATA[四代ALK抑制剂TPX-0131开启1/2期临床研究]]></content:encoded><pubDate>Sun, 25 Apr 2021 15:39:10 +0800</pubDate></item><item><title>看新闻 涨知识 I 武田法布雷病新药中国上市</title><link>https://mp.weixin.qq.com/s/exzx6fEZCxBzSq2UY68D5A</link><description></description><content:encoded><![CDATA[看新闻 涨知识 I 武田法布雷病新药中国上市]]></content:encoded><pubDate>Sat, 24 Apr 2021 20:55:57 +0800</pubDate></item><item><title>2021 CSCO指南会次日｜更新再度来袭，消化、营养、免疫等指南亮点不断，速来围观！</title><link>https://mp.weixin.qq.com/s/UXVqKy3hxVkZRmd1Wr2EJQ</link><description></description><content:encoded><![CDATA[2021 CSCO指南会次日｜更新再度来袭，消化、营养、免疫等指南亮点不断，速来围观！]]></content:encoded><pubDate>Sat, 24 Apr 2021 20:55:57 +0800</pubDate></item><item><title>【2021 CSCO指南会】血液肿瘤相关指南更新亮点（合集）</title><link>https://mp.weixin.qq.com/s/00sEX26bVaH7ZZfFGuhdFg</link><description></description><content:encoded><![CDATA[【2021 CSCO指南会】血液肿瘤相关指南更新亮点（合集）]]></content:encoded><pubDate>Sat, 24 Apr 2021 20:55:57 +0800</pubDate></item><item><title>一线奥希替尼→二线达可替尼的二期临床研究结果</title><link>https://mp.weixin.qq.com/s/YOO6wvMxPGl-Efc266YQsw</link><description></description><content:encoded><![CDATA[一线奥希替尼→二线达可替尼的二期临床研究结果]]></content:encoded><pubDate>Sat, 24 Apr 2021 20:55:57 +0800</pubDate></item><item><title>读NEJM 涨知识 I ADC药物治疗三阴乳腺癌III期临床研究结果</title><link>https://mp.weixin.qq.com/s/8NMJnH1on3HITvqgjT1e0g</link><description></description><content:encoded><![CDATA[读NEJM 涨知识 I ADC药物治疗三阴乳腺癌III期临床研究结果]]></content:encoded><pubDate>Fri, 23 Apr 2021 22:19:55 +0800</pubDate></item><item><title>【2805】2021 CSCO指南会首日 | 带您玩转六大专场更新要点，聚焦中国临床诊疗实践</title><link>https://mp.weixin.qq.com/s/XSHBRm5YPL-1-MGx2yji-Q</link><description></description><content:encoded><![CDATA[【2805】2021 CSCO指南会首日 | 带您玩转六大专场更新要点，聚焦中国临床诊疗实践]]></content:encoded><pubDate>Fri, 23 Apr 2021 22:19:55 +0800</pubDate></item></channel></rss>